Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 213 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Protozoan Infections Clear all
Completed Phase 1Phase 2 Interventional Results available

Use of Sodium Stibogluconate as a Treatment for Leishmaniasis

NCT00657618
View directory record Official record
Conditions
Leishmaniasis
Interventions
Sodium Stibogluconate (SSG)
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 1 Interventional

A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea

NCT00001018
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Letrazuril
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Not applicable Interventional

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

NCT00000666
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers

NCT01484548
View directory record Official record
Conditions
Leishmaniasis
Interventions
LEISH-F3 + GLA-SE, LEISH-F3 alone
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria

NCT00870987
View directory record Official record
Conditions
Malaria
Interventions
DNA vaccine prime, adenovirus type 5 vaccine boost
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine Thorough QTc Study in Healthy Subjects

NCT01928914
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg, moxifloxacin, Placebo for Tafenoquine, Placebo for moxifloxaxin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Culver City, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine

NCT00844207
View directory record Official record
Conditions
Malaria
Interventions
Fixed combination of Azithromycin and Chloroquine, Azithromycin and Chloroquine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 21, 2009 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Mortality Reduction After Oral Azithromycin: Morbidity Study

NCT02048007
View directory record Official record
Conditions
Childhood Mortality
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month and older
Enrollment
72,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

NCT03824236
View directory record Official record
Conditions
Malaria
Interventions
RTS,S/AS01E (SB257049)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 1, 2026, 4:09 PM EDT
Completed No phase listed Observational

Congenital Transmission of Lineages I and II of Trypanosoma Cruzi

NCT01787968
View directory record Official record
Conditions
Chagas Disease
Interventions
Not listed
Lead sponsor
Tulane University School of Public Health and Tropical Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
28,348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

NCT01857869
View directory record Official record
Conditions
Malaria
Interventions
GSK257049 Dosage 1, GSK257049 Dosage 2, Sporozoite-infected mosquitoes challenge
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 1, 2026, 4:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision

NCT06951438
View directory record Official record
Conditions
Sexually Transmitted Disease (STD), Gonorrhea, Chlamydia, Trichomonas Infection
Interventions
Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas
Diagnostic Test
Lead sponsor
Queen's Medical Center
Other
Eligibility
14 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Experimental Vaccine for Plasmodium Falciparum Malaria

NCT00340431
View directory record Official record
Conditions
Plasmodium Falciparum Malaria, Vaccines
Interventions
MSP1(42)-FVO & MSP1(42)-3D7
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

NCT00761020
View directory record Official record
Conditions
Malaria
Interventions
Mefloquine, Control
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 1, 2026, 4:09 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali

NCT00863408
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen

NCT03934450
View directory record Official record
Conditions
Malaria, Glucose 6 Phosphate Dehydrogenase Deficiency
Interventions
RPQ, SPQ, Primaquine Phosphate, Placebo
Drug
Lead sponsor
University of Mississippi, Oxford
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 1, 2026, 4:09 PM EDT
Completed No phase listed Observational

DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women

NCT01874158
View directory record Official record
Conditions
Trichomonas Vaginitis
Interventions
Not listed
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

NCT02015091
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 1, 2026, 4:09 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

NCT03278808
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine-Azithromycin (CQ/AZ), Chloroquine (CQ), atovaquone-proguanil (Malarone®)
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

NCT02174978
View directory record Official record
Conditions
Malaria
Interventions
FMP012 with AS01B adjuvant system, P falciparum Controlled Human Malaria Infection (CHMI)
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 1, 2026, 4:09 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents

NCT01843491
View directory record Official record
Conditions
Healthy, Malaria
Interventions
Ad-PfCA
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 1, 2026, 4:09 PM EDT
Recruiting Phase 2 Interventional

Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

NCT06207370
View directory record Official record
Conditions
Babesiosis
Interventions
Tafenoquine, Placebo
Drug · Other
Lead sponsor
60 Degrees Pharmaceuticals LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 1, 2026, 4:09 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

CS DNA MVA Trial in Mampong, Ghana

NCT00377494
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
MVA-CSO Vaccine, PfCSP DNA (VCL-2510) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2008
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 1, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis

NCT00884377
View directory record Official record
Conditions
Cutaneous Leishmaniasis
Interventions
Sodium stibogluconate (Pentostam), ThermoMed
Drug · Device
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 1, 2026, 4:09 PM EDT